Novel agent for treatment of cerebral stroke and other diseases with neuronal damage in clinical phase I
Lu AA24493 is a novel carbamoylated form of human erythropoietin (EPO) - a modification of EPO that results in loss of haematopoietic effects but maintains the tissue protective effect. These tissue protective effects translate to very positive effects in a number of animal models for neuronal damage including models for cerebral stroke.
"There is a significant medical need for effective treatments within stroke and Lu AA24493 offers a novel approach to a disease with few treatment options today," says Peter Høngaard Andersen, Head of Research at Lundbeck. He continues: "We are very pleased that our scientists have successfully advanced Lu AA24493 to clinical development."
Lu AA24493 was developed as part of the collaboration between H. Lundbeck A/S and Warren Pharmaceuticals, Inc. and it is licensed from Warren Pharmaceuticals under the license agreement that the companies announced in 2002. Under that agreement Lundbeck holds worldwide rights for indications related to the central nervous system.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.